Alzheimer’s new treatment 2026 is no longer just a headline — it is a clinical reality changing lives for seniors diagnosed with early Alzheimer’s disease. Two groundbreaking drugs, Leqembi (lecanemab) and Donanemab (Kisunla), have received FDA approval and are now being administered in clinics across the country. If you or a loved one has been recently diagnosed with mild cognitive impairment or early Alzheimer’s, this guide explains everything you need to know right now.
What Are Leqembi and Donanemab? How Do They Work?
Both drugs belong to a class called anti-amyloid monoclonal antibodies. They target amyloid plaques — the sticky protein clumps in the brain that are a hallmark of Alzheimer’s disease. By clearing these plaques, the drugs aim to slow the progression of cognitive decline rather than simply masking symptoms. Leqembi (lecanemab), developed by Eisai and Biogen, received full FDA approval in July 2023. Clinical trials showed it slowed cognitive decline by approximately 27% compared to placebo over 18 months. Donanemab (Kisunla), developed by Eli Lilly, received full FDA approval in July 2024. The TRAILBLAZER-ALZ 2 trial showed it slowed decline by up to 35% in patients with low-to-medium tau protein levels, and approximately 72% of participants could stop treatment after 12 months once plaques were cleared.
Who Qualifies for Alzheimer’s Treatments in 2026?
These drugs are not for everyone with Alzheimer’s. They are specifically indicated for patients with early symptomatic Alzheimer’s disease: mild cognitive impairment (MCI) due to Alzheimer’s, mild Alzheimer’s dementia (early stage), and confirmed amyloid pathology via PET scan or cerebrospinal fluid test. They are not appropriate for moderate or severe Alzheimer’s — clinical evidence does not support use at those stages. Patients on blood thinners such as warfarin face higher ARIA risk and require careful individual assessment.
| Drug | Dosing | Trial Slowing of Decline | Duration |
|---|---|---|---|
| Leqembi (lecanemab) | IV every 2 weeks | ~27% | Ongoing (chronic) |
| Donanemab (Kisunla) | IV monthly | Up to 35% | ~12 months then stop |
Does Medicare Cover Leqembi and Donanemab in 2026?
Yes — this is the critical update for 2026. Medicare covers FDA-approved anti-amyloid Alzheimer’s therapies under Medicare Part B following a revised National Coverage Determination. Coverage includes the drug infusion itself (80% after the $283 Part B deductible), required amyloid PET scans for confirmed diagnosis, and monitoring MRIs for ARIA. Coverage requires the prescribing physician to participate in a CMS-approved registry. Out-of-pocket costs under Original Medicare can reach $5,000–$20,000 per year after the 20% coinsurance, making Medigap Plan G or a comprehensive Medicare Advantage plan highly valuable. Manufacturer patient assistance programs are available for lower-income patients.
Understanding ARIA — The Key Safety Risk
The most important safety concern with both drugs is ARIA (Amyloid-Related Imaging Abnormalities) — brain swelling (ARIA-E) or microbleeds (ARIA-H) detected on MRI. ARIA occurred in about 37% of Leqembi patients (most asymptomatic), with symptomatic ARIA in about 3% and serious ARIA requiring hospitalization in under 1%. APOE e4 gene carriers face significantly higher ARIA risk. Regular MRI monitoring is mandatory — typically before treatment and at specific intervals during the first year. Patients with pre-existing small vessel disease or those on blood thinners require especially careful evaluation by a specialist.
5 Steps for Seniors to Access These Treatments in 2026
- Get a formal cognitive evaluation — Ask your primary care doctor for a referral to a neurologist or memory center. Bring a family member who can describe changes they have noticed.
- Confirm amyloid pathology — An amyloid PET scan or CSF biomarker test is required before treatment. Medicare covers one amyloid PET per patient with appropriate documentation.
- Get genotyped for APOE e4 — Genetic testing helps assess ARIA risk. Having one or two copies of APOE e4 significantly changes the risk-benefit calculation.
- Verify Medicare coverage and costs — Call 1-800-MEDICARE or visit Medicare.gov. Ask about manufacturer patient assistance programs if costs are prohibitive.
- Find a certified infusion center — Contact the Alzheimer’s Association helpline at 1-800-272-3900 to locate certified treatment centers near you.
Lifestyle Strategies That Complement Drug Therapy
Whether or not you qualify for anti-amyloid therapy, these evidence-based strategies protect brain health and work alongside any treatment. Aim for 150 minutes of moderate aerobic exercise per week — research shows exercise increases BDNF and reduces amyloid buildup. Follow the MIND diet rich in leafy greens, berries, fish, olive oil, and nuts, which is associated with a 21% lower dementia risk in observational studies. Prioritize 7–9 hours of quality sleep, as the brain clears amyloid during deep sleep via the glymphatic system. Control blood pressure to under 130/80 — midlife hypertension is a major modifiable Alzheimer’s risk factor. Stay socially engaged and mentally active through learning new skills and maintaining social connections.
Honest Perspective: What These Drugs Can and Cannot Do
Slowing cognitive decline by 27–35% is genuinely significant — it may mean an extra 6–12 months of independence, clear communication with loved ones, and maintained dignity. For a disease that had no disease-modifying treatment for 20 years, this represents a real breakthrough. However, these drugs do not cure Alzheimer’s disease and do not restore lost memory. They slow the progression. Research is accelerating rapidly, with combination therapies targeting tau protein, neuroinflammation, and synaptic health currently in clinical trials. The next 3–5 years promise even more meaningful advances for Alzheimer’s patients and families.
Sources
1. FDA — Leqembi (lecanemab) Prescribing Information
2. National Institute on Aging — Alzheimer’s Disease Treatment
3. Medicare.gov — Treatments for Alzheimer’s Disease
Related Articles You May Find Helpful
- Memory Loss vs. Dementia in Seniors 2026: How to Tell the Difference
- Medicare Cancer Treatment Coverage 2026: What Seniors Must Know
- NAD+ Supplements for Seniors 2026: The Anti-Aging Molecule Explained
- Potassium for Seniors 2026: Benefits, Deficiency Signs & Best Foods
- Vertigo in Seniors 2026: Causes, Treatment & Fall Prevention Guide
